CD19 and B-cell chronic lymphocytic leukemia: A ROR1-directed CAR was selected since this molecule is under development for treatment of CLL and other malignancies (60, 61), and the CD19-directed CAR was chosen to validate the study results as it remains the gold standard for the field.